MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
P/E ratio for MiNK Therapeutics, Inc. (INKT)
P/E ratio as of 2023: -1.64
According to MiNK Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.64. At the end of 2022 the company had a P/E ratio of -3.55.
P/E ratio history for MiNK Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.64 |
| 2022 | -3.55 |
| 2021 | -6.46 |
| 2020 | -25.32 |
| 2019 | -15.32 |